PITTSBURGH, May 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Sumatriptan Succinate Tablets 25 mg (base), 50 mg (base) and 100 mg (base).

Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine headaches. They are the generic version of GlaxoSmithKline's Imitrex^® Tablets, which had annual U.S. sales of approximately $878 million as of March 31, 2006.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Laboratories Inc.

Patrick Fitzgerald, or Kris King of Mylan Laboratories Inc., +1-724-514-1800